Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals
This invention, developed by the CDC and collaborators, entails a live, attenuated recombinant rabies virus vaccine that can elicit an effective anti-rabies immune response in animal recipients. Inoculation with a live, attenuated, rabies virus allows for the optimized production of immunity in the absence of pathogenicity. Oral administration of rabies vaccines is often a preferred route of vaccine delivery because it is most effective in wildlife. Unfortunately, availability of an oral vaccine for canines has been a significant hurdle to date.
This vaccine technology could be used for immunization of stray dogs by an oral route. In developing nations, more than 90% of human exposure events and 99% of human deaths due to rabies are caused by rabid dogs. Using this vaccine with a broadly implemented oral vaccination strategy provides a promising opportunity for reducing transmission of rabies between stray dogs and, thereby, increasing protection for people.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Development Stage:
- In vitro data available
- In vivo data available (animal)
Inventors:
Charles Rupprecht (CDC) ➽ more inventions...
Intellectual Property:
U.S. Pat: 7,074,413 issued 2006-07-11
PCT Application No. PCT/US2001/009529
US Application No. 09/816,531
US Application No. 60/191,510
Publications:
Morimoto K, et al. PMID 11348722
Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518
OTT Reference No: E-470-2013-0
Updated: May 24, 2016